TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18628419
Drug: CEE 0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg alone
Study: 18628419
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + daily medroxyprogesterone acetate (MPA) 2.5 mg
Study: 18628419
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + cyclical MPA (10 mg days 1‐12 per 28‐day cycle)
Study: 18628419
Drug: CEE +
Normalized name: Conjugated Estrogen Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE + cyclical micronized progesterone (10 mg days 1‐12)
Study: 12244891
Drug: 240 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/die Egb 761 (group I = 50 patients)
Study: 12244891
Drug: 60 mg/die
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg/die Egb 761 (group II = 49 patients)
Study: 394275
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (Diclofenac and Indomethacin)
Study: 26359580
Drug: Sequential scanning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential scanning technique
Study: 23115402
Drug: Phentermine 15
Normalized name: phentermine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine 15 mg plus extended-release topiramate 92 mg
Study: 20216464
Drug: L-carnitine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine (20 mg kg(‐1) i.v.)
Study: 17977294
Drug: No antimicrobial
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antimicrobial agent (control; n = 15)
Study: 15743361
Drug: Terlipressin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terlipressin (2 mg IV bolus, n = 22)
Study: 15743361
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of somatostatin (500 microg/h, n = 20)
Study: 11666118
Drug: Total triterpenic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total triterpenic fraction of Centella asiatica (TTFCA), 60 mg, oral tablets, thrice daily for 12 months
Study: 9638783
Drug: Adjuvant Psychological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant Psychological Therapy (APT)
Study: 3290413
Drug: Methylphenidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate (0.3 mg/kg/dose twice daily for 2 weeks)
Study: 24984785
Drug: ATX-101 1
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 1 mg/cm²
Study: 24984785
Drug: ATX-101 2
Normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATX-101 2 mg/cm²
Study: 19080399
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of prednisone for 7 days
Study: 19080399
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of prednisone for 10 days, then tapered to 15 mg/d for 4 days
Study: 10553827
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg midazolam
Study: 2008949
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg midazolam
Study: 6853286
Drug: CVE (central
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVE (central vascular engorgement) via G-suit inflation
Study: 26817718
Drug: Plasma 25(OH)D
Normalized name: 1α,25(OH)2D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma 25(OH)D concentration ≥ 10 ng/mL compared with <10 ng/mL for women with alcohol intake ≥ 7.1 g/d
Study: 10358462
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard conservative treatment without octreotide)
Study: 2663610
Drug: Clonidine (0.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.9 mg/24 h orally for 72 h)
Study: 766572
Drug: Lidoflazine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidoflazine (60 mg tablet t.i.d.)
Study: 20530316
Drug: Accelerated-fractionation radiotherapy
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated-fractionation radiotherapy combined with cisplatin therapy
Study: 20530316
Drug: Standard-fractionation radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-fractionation radiotherapy combined with cisplatin therapy
Study: 2668407
Drug: Atenolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (mean dose 67 mg/day)
Study: 2668407
Drug: Diltiazem (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (mean dose 329 mg/day)
Study: 19672264
Drug: Gemcitabine (G)
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine (G) 1000 mg m(‐2) on D1, 8, 15 q28d (Arm A)
Study: 19672264
Drug: Cisplatin (C)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (C) 25 mg m(‐2) followed by Gemcitabine (G) 1000 mg m(‐2) D1, 8 q21d (Arm B)
Study: 9240593
Drug: Ultralow dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultralow dose of parenteral estradiol (7.5 microg/24 hours) delivered by vaginal rings
Study: 8204230
Drug: GA/PM (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA/PM (general anesthesia-parenteral morphine as needed)
Study: 8204230
Drug: EA/PM (epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA/PM (epidural anesthesia-parenteral morphine as needed)
Study: 8204230
Drug: EA/EM (epidural
Approvals — FDA: no, EMA: no, PMDA: no
Description: EA/EM (epidural anesthesia-epidural morphine 4 to 5 mg)
Study: 31749018
Drug: Partial Intervention
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial Intervention (PI), homotaurine administration (100 mg/die) and lessons on the Mediterranean diet
Study: 28495209
Drug: Moral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moral and conventional rules in daily life
Study: 26660396
Drug: Basic instructions
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic instructions of oral hygiene (control group)
Study: 24393153
Drug: Topical regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical regular crystalline insulin (containing zinc)
Study: 24393153
Drug: Aqueous zinc
Normalized name: ethylcellulose aqueous dispersion type A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous zinc chloride solution
Study: 22836067
Drug: Niacin therapy
Normalized name: Niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin therapy
Study: 19561649
Drug: Oral beclomethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral beclomethasone dipropionate (BDP)
Study: 29401239
Drug: Targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapy of underlying conditions (including mineralocorticoid receptor antagonists, statins, ACE inhibitors/ARBs, and cardiac rehabilitation)
Study: 26670823
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for insomnia, delivered in a five-session format.
Study: 26670823
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) for insomnia delivered by mental health practitioners.
Study: 24447519
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (current therapy)
Study: 23049836
Drug: Monthly installment
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly installment schedule
Study: 17539894
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.i.d. with naltrexone 50 mg
Study: 17539894
Drug: Tegaserod 6
Normalized name: tegaserod 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegaserod 6 mg b.i.d. and Tegaserod with naltrexone 50 mg
Study: 9412612
Drug: Piracetam (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (12 g as an initial intravenous bolus, 12 g daily for 4 weeks, and 4.8 g daily for 8 weeks)
Study: 9412612
Drug: Piracetam (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (in early treatment subgroup)
Study: 9412612
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in early treatment subgroup)
Study: 8213795
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa solution
Study: 25439595
Drug: sham/0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham/0.5 mg crossover
Study: 12743672
Drug: Ximelagatran 20
Normalized name: Ximelagatrán
DrugBank: Ximelagatran (DB04898)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ximelagatran 20 mg twice daily, administered either before breakfast and with dinner, or with breakfast and after dinner.
Study: 12743672
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of ximelagatran (1-98 mg) in a dose-escalation study.
Study: 8362451
Drug: Mebendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole (400 mg)
Study: 20462038
Drug: Kangliu Zengxiao
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangliu Zengxiao Decoction (KLZX) in addition to chemotherapy NP regimen
Study: 20462038
Drug: Chemotherapy NP
Normalized name: NP Thyroid Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy NP regimen alone
Study: 18678792
Drug: Sustained-release bupropion
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sustained-release bupropion hydrochloride started at 150 mg/d and increased to 400 mg/d
Study: 18678792
Drug: Sertraline hydrochloride
Normalized name: sertraline hydrochloride
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline hydrochloride started at 50 mg/d and increased to 200 mg/d
Study: 18678792
Drug: Extended-release venlafaxine
Normalized name: venlafaxine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release venlafaxine hydrochloride started at 37.5 mg/d and increased to 375 mg/d
Study: 15900007
Drug: Doxorubicin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (50 mg/m2) plus docetaxel (75 mg/m2)
Study: 15900007
Drug: Doxorubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (60 mg/m2) plus cyclophosphamide (600 mg/m2)
Study: 8712652
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulphate (MST) and 10 mg metoclopramide every 8 h for 48 h
Study: 8712652
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg diclofenac twice daily for 48 h
Study: 8712652
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg morphine sulphate (MST)
Study: 1655107
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg day‐1) for 4 weeks
Study: 1655107
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg day‐1) for 52 weeks
Study: 7035745
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy including platinum
Study: 29989335
Drug: Insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin degludec U100 (Deg)
Study: 25030181
Drug: Exenatide 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide 2.5 µg + insulin
Study: 16183427
Drug: Insulin alone
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin alone (control)
Study: 25030181
Drug: Pramlintide 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramlintide 30 µg + insulin
Study: 14741079
Drug: Rofecoxib 50
Normalized name: rofecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 50 mg/day for 6 days
Study: 7506144
Drug: Nimesulide 200
Normalized name: nimesulide 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide 200 mg/day
Study: 9777717
Drug: Erig PMC
Normalized name: Erigeron strigosus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erig PMC (40 IU kg(‐1) via intramuscular route)
Study: 9777717
Drug: PHT‐Erig (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT‐Erig (40 IU kg(‐1) via intramuscular route)
Study: 9777717
Drug: Erig PMC
Normalized name: Erigeron strigosus whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erig PMC (40 IU kg(‐1) via intramuscular route) with PVRV
Study: 9777717
Drug: PHT‐Erig (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHT‐Erig (40 IU kg(‐1) via intramuscular route) with PVRV
Study: 2460568
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon gel (10^6 IU of leukocyte interferon/g)
Study: 2460568
Drug: Topical interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical interferon gel with nonoxynol-9
Study: 2460568
Drug: Placebo (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (gel base alone)
Study: 31595423
Drug: CoQ10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (300 mg, once daily) for 12 months in RTT patients
Study: 31595423
Drug: CoQ10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CoQ10 (300 mg) for 30 days in healthy adults
Study: 31595423
Drug: EGCG (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGCG (1 g green tea extract containing 50% EGCG) for 30 days in healthy adults
Study: 31595423
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C (1 g) for 30 days in healthy adults
Study: 31595423
Drug: Resveratrol (325
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol (325 mg) for 30 days in healthy adults
Study: 23688751
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab combined with glucocorticoids (prednisone 60, 30, 20, 10 mg/day on days 5-28)
Study: 23688751
Drug: Low-dose rituximab
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose rituximab combined with glucocorticoids (prednisone)
Study: 23688751
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (dexamethasone 40 mg/day on days 1-4, followed by rituximab 100 mg on days 7, 14, 21, 28)
Study: 17315708
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus 10 longidase injections in a dose of 3000 IU
Study: 12817526
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg alone for 10 days
Study: 12817526
Drug: Digoxin 0.25
Normalized name: digoxin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digoxin 0.25 mg with Crataegus special extract WS 1442 (hawthorn) 450 mg twice daily for 21 days
Study: 10917408
Drug: Gabapentin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (600 to 3,600 mg/day)
Study: 8672615
Drug: Metamizol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metamizol (1 g/100 ml NaCl 0.9%)
Study: 8672615
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml NaCl 0.9%)
Study: 6375890
Drug: Injections of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injections of tyrosine-adsorbed, glutaraldehyde-modified Dermatophagoides pteronyssinus antigen
Study: 30100320
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SS and remote MFR
Study: 30100320
Drug: Self‐administered interventions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self‐administered interventions (all groups)
Study: 27051992
Drug: Caffeinated drink
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated drink (80 mg of caffeine)
Study: 25725933
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC 10-mg
Study: 25725933
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC 20-mg
Study: 25725933
Drug: Oral THC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral THC (10-mg and/or 20-mg)
Study: 23593607
Drug: ETV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV (1 mg) monotherapy
Study: 23593607
Drug: LAM+ADV combination
Normalized name: Viril Lam
Approvals — FDA: no, EMA: no, PMDA: no
Description: LAM+ADV combination therapy
Study: 23593607
Drug: ETV (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV (1 mg)+ADV combination therapy
Study: 18389339
Drug: Benidipine administered
Normalized name: manidipine
DrugBank: Manidipine (DB09238)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine administered orally for 4 weeks
Study: 18389339
Drug: Benidipine with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benidipine with L-arginine
Study: 8181831
Drug: Porous hydroxyapatite
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous hydroxyapatite in granules (HA-G)
Study: 3083212
Drug: Sorbinil (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorbinil (250 mg qd)
Study: 29572130
Drug: Telephone-delivered exercise
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-delivered exercise therapy by physiotherapists
Study: 24894077
Drug: Both therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both therapies (individual HT and CD-based HT)
Study: 18231889
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus acupuncture (n=125)
Study: 18231889
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus specific stabilising exercises (n=131)
Study: 18231889
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment alone (n=130)
Study: 8831438
Drug: Lithium doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium doses adjusted to achieve a serum lithium concentration of 0.8 to 1.0 mmol/liter (standard)
Study: 8831438
Drug: Lithium doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium doses adjusted to achieve a serum lithium concentration of 0.4 to 0.6 mmol/liter (low)
Study: 1426392
Drug: Subconjunctival antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subconjunctival antibiotics and steroids
Study: 1426392
Drug: Topical antibiotics
Normalized name: Tetracycline and derivatives, topical antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical antibiotics and steroids
Study: 3897156
Drug: Mixed-beam treatment
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-beam treatment (neutron/photon)
Study: 3897156
Drug: Photon radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Photon radiation therapy (X ray)
Study: 27392137
Drug: Donepezil 5
Normalized name: donepezil 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 5 mg daily
Study: 23361084
Drug: secukinumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab (10 mg/kg)
Study: 8168348
Drug: Roxithromycin 150
Normalized name: roxithromycin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin 150 mg twice daily for 7 days
Study: 28364504
Drug: Tiagabine 12
Normalized name: tiaGABine 12 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine 12 mg
Study: 22082303
Drug: Alkalinized lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alkalinized lidocaine and heparin
Study: 19708504
Drug: 131I treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I treatment with oral methyloprednisolone (MP) over 30 days starting at 16 mg/day
Study: 19708504
Drug: 131I treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 131I treatment
Study: 17536225
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment adjustment (increase or decrease)
Study: 17536225
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (41 matched patients, treatment unchanged)
Study: 17536225
Drug: Study group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group (adjusted treatment)
Study: 15601804
Drug: Bosentan 31.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 31.25 mg
Study: 15601804
Drug: Bosentan 62.5
Normalized name: bosentan 62.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 62.5 mg
Study: 24656288
Drug: Bosentan 125
Normalized name: bosentan 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan 125 mg
Study: 15601804
Drug: Bosentan 250
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 250 mg
Study: 10392325
Drug: Bosentan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (all doses)
Study: 11860412
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, clarithromycin 500 mg, and amoxicillin 1 g (LAC)
Study: 11860412
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 500 mg (LMC)
Study: 10453438
Drug: Combination low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination low fat and low energy diet
Study: 2216204
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg prostaglandin E2 gel intracervically (N = 52)
Study: 2216204
Drug: 3 mg
Normalized name: boron 3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg prostaglandin E2 gel intravaginally (N = 48)
Study: 350861
Drug: Penfluridol (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penfluridol (administered once weekly)
Study: 350861
Drug: Trifluoperazine (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluoperazine (administered daily)
Study: 28235027
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ALVAC-HIV and AIDSVAX B/E gp120
Study: 17413093
Drug: Soymilk diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soymilk diet (37.5 g/d)
Study: 15197520
Drug: Intravenous desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous desmopressin (2 microg)
Study: 15197520
Drug: Oral desmopressin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral desmopressin (0.2 mg)